NLS Pharmaceutics Ltd.
Clinical-stage biopharma firm developing therapies for rare and complex CNS disorders.
NLSP | US
Overview
Corporate Details
- ISIN(s):
- CH0523961370 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- THE CIRCLE 6, 0 ZURICH
- Website:
- https://nlspharma.com/
Description
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for patients with rare and complex central nervous system (CNS) disorders. The company's primary focus areas include sleep disorders, neurodegenerative diseases, and attention-deficit/hyperactivity disorder (ADHD). Its lead product candidates are Quilience, a proprietary extended-release formulation of mazindol for the treatment of narcolepsy, and Nolazol for ADHD. NLS Pharmaceutics is also advancing its pipeline with additional assets, such as the AEX-6xx series, to address other CNS-related conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-04 13:15 |
6-K - NewcelX Ltd. (0001783036) (Filer)
|
English | 17.3 KB |
Automate Your Workflow. Get a real-time feed of all NLS Pharmaceutics Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NLS Pharmaceutics Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NLS Pharmaceutics Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
